口服葡萄糖耐受性测试作为发生移植后糖尿病的风险标志物
Matheus Rizzato Rossi1, Marilda Mazzali1, Marcos Vinicius de Sousa1
1Renal Transplant Research Laboratory, Renal Transplant Unit, Division of Nephrology, Department of Internal Medicine, School of Medical Sciences, University of Campinas-UNICAMP, Campinas, São Paulo, Brazil.
Transplantation proceedings
|May 18, 2024
概括
通过口服葡萄糖耐受性测试发现的移植前葡萄糖耐受性受损与移植后的糖尿病有关. 这一发现可能有助于预测以前没有糖尿病的移植患者的PTDM风险.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
- 移植医学 移植医学 移植医学
背景情况:
- 移植后糖尿病 (PTDM) 在6个月内影响多达30%的移植接受者,增加死亡率和移植失败风险.
- 目前没有可靠的生物标志物用于预测PTDM发展.
- 这项研究调查了移植前口服葡萄糖耐受性测试 (OGTT) 对PTDM发病率的预测价值.
研究的目的:
- 评估异常移植前OGTT结果与PTDM发生率之间的关联.
- 在移植候选人中识别PTDM的潜在早期指标.
主要方法:
- 成年已故捐赠移植接受者的回顾性单中心研究 (2021年3月 - 2022年6月).
- 包括50名患者,不包括那些患有先前存在的糖尿病,死亡或6个月内移植失败的患者.
- 分析了移植前的OGTT,空腹血葡萄糖 (FPG) 和移植后的FPG水平.
主要成果:
- 9名患者 (18%) 患有PTDM,其中44%发生在移植后3-6个月之间.
- 患有PTDM的患者在移植前的FPG平均值显著高 (85.7±7.9比79.1±8.2,P=0.03).
- 在移植前的OGTT上,显著增加的PTDM患者被归类为葡萄糖耐受性受损 (IGT).
结论:
- 移植前葡萄糖耐受性受损与发展PTDM的风险增加有关.
- OGTT可以作为一种有价值的工具,用于识别患有PTDM风险较高的移植接受者.
- 早期识别IGT可以促进及时干预,以减轻PTDM的发展.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Diabetes: Symptoms, Diagnosis, and Complications
524
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
524
Glucose Transporters
22.7K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.7K
Hypoglycemia and Glucagon
256
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
256
Diabetes Mellitus: Overview and Type I Subtype
2.6K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.6K
Oral Hypoglycemic Agents: Glinides
153
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
153


